Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 11.84 SEK -6.55%
Market Cap: 552.8m SEK
Have any thoughts about
Moberg Pharma AB (publ)?
Write Note

Relative Value

The Relative Value of one MOB stock under the Base Case scenario is 0.56 SEK. Compared to the current market price of 11.84 SEK, Moberg Pharma AB (publ) is Overvalued by 95%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MOB Relative Value
Base Case
0.56 SEK
Overvaluation 95%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
39
vs Industry
0
Median 3Y
89.7
Median 5Y
31.1
Industry
2.6
Forward
63.9
vs History
vs Industry
Median 3Y
-16.4
Median 5Y
-9.9
Industry
22.3
Forward
-24.6
vs History
vs Industry
Median 3Y
-18.4
Median 5Y
-29.1
Industry
17.5
vs History
vs Industry
Median 3Y
-14.9
Median 5Y
-15.2
Industry
24.8
vs History
73
vs Industry
26
Median 3Y
1
Median 5Y
2.3
Industry
2.1
vs History
36
vs Industry
0
Median 3Y
-34.6
Median 5Y
29.9
Industry
2.7
Forward
28.3
vs History
30
vs Industry
0
Median 3Y
0
Median 5Y
27.7
Industry
5.3
vs History
vs Industry
52
Median 3Y
-21.8
Median 5Y
-16.4
Industry
13.4
Forward
-9.8
vs History
vs Industry
49
Median 3Y
-20.1
Median 5Y
-20.1
Industry
16.8
Forward
-9.4
vs History
vs Industry
51
Median 3Y
-16.6
Median 5Y
-28
Industry
15.9
vs History
vs Industry
38
Median 3Y
-16.6
Median 5Y
-28
Industry
18.5
vs History
73
vs Industry
27
Median 3Y
1
Median 5Y
2.6
Industry
1.9

Multiples Across Competitors

MOB Competitors Multiples
Moberg Pharma AB (publ) Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Moberg Pharma AB (publ)
STO:MOB
580.7m SEK 110.1 -23.8 -9.4 -8.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
788.1B USD 19.3 94.2 50.5 56.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK 13.1 37.5 25 28.7
US
Johnson & Johnson
NYSE:JNJ
384.8B USD 4.4 26.2 12.6 16.5
US
Merck & Co Inc
NYSE:MRK
259.4B USD 4.2 18.9 12.8 15.8
CH
Roche Holding AG
SIX:ROG
215.3B CHF 3.7 18.7 10.5 12.5
UK
AstraZeneca PLC
LSE:AZN
171.2B GBP 4.5 34.3 170.5 255.6
CH
Novartis AG
SIX:NOVN
184.8B CHF 4.4 13.2 10.5 15.5
US
Pfizer Inc
NYSE:PFE
160.4B USD 2.7 37.7 11 16.7
P/E Multiple
Earnings Growth
SE
Moberg Pharma AB (publ)
STO:MOB
Average P/E: 35.1
Negative Multiple: -23.8
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
94.2
454%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
37.5
89%
US
Johnson & Johnson
NYSE:JNJ
26.2
-22%
US
Merck & Co Inc
NYSE:MRK
18.9
7 426%
CH
Roche Holding AG
SIX:ROG
18.7
30%
UK
AstraZeneca PLC
LSE:AZN
34.3
175%
CH
Novartis AG
SIX:NOVN
13.2
19%
US
Pfizer Inc
NYSE:PFE
37.7
712%
EV/EBIT Multiple
EBIT Growth
SE
Moberg Pharma AB (publ)
STO:MOB
Average EV/EBIT: 2 013.3
Negative Multiple: -8.9
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A
US
Eli Lilly and Co
NYSE:LLY
56.4
212%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
DK
Novo Nordisk A/S
CSE:NOVO B
28.7
85%
US
Johnson & Johnson
NYSE:JNJ
16.5
29%
US
Merck & Co Inc
NYSE:MRK
15.8
695%
CH
Roche Holding AG
SIX:ROG
12.5
27%
UK
AstraZeneca PLC
LSE:AZN
255.6
131%
CH
Novartis AG
SIX:NOVN
15.5
54%
US
Pfizer Inc
NYSE:PFE
16.7
63%

See Also

Discover More
Back to Top